Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
+1.25 (1.49%)
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 82.13 - 85.33
52 week 31.38 - 86.92
Open 83.96
Vol / Avg. 773,700.00/1.39M
Mkt cap 7.74B
P/E     -
Div/yield     -
EPS -4.83
Shares 91.49M
Beta 3.00
Inst. own 91%
Aug 2, 2017
Q2 2017 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 15, 2017
Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference
Jun 6, 2017
Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference - Webcast
May 31, 2017
Alnylam Pharmaceuticals Inc at Boston Biotech Boston CEO Conference
May 18, 2017
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
May 5, 2017
Q1 2017 Alnylam Pharmaceuticals Inc Earnings Release
May 5, 2017
Q1 2017 Alnylam Pharmaceuticals Inc Earnings Call - Webcast
May 2, 2017
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting
Apr 5, 2017
Alnylam Pharmaceuticals Inc at Needham Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -565.88% -869.63%
Operating margin -561.77% -900.33%
EBITD margin - -868.25%
Return on average assets -35.91% -30.96%
Return on average equity -49.15% -37.54%
Employees 514 -
CDP Score - -


300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Barry E. Greene President
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Manmeet S. Soni Chief Financial Officer, Senior Vice President, Principal Financial Officer
Age: 39
Bio & Compensation  - Reuters
Yvonne L. Greenstreet M.D. Chief Operating Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development
Age: 54
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President, General Counsel, Secretary
Age: 62
Bio & Compensation  - Reuters
Pushkal Garg M.D. Senior Vice President - Clinical Development, Chief Medical Officer
Bio & Compensation  - Reuters
Theresa Heggie Senior Vice President, Head of Europe and Canada
Bio & Compensation  - Reuters
Peter F. Smith Ph.D. Senior Vice President - Early Development
Age: 59
Bio & Compensation  - Reuters